Causes of death in patients undergoing percutaneous coronary intervention with drug-eluting stents in a real-world setting

Journal of Invasive Cardiology

Volumn 21, Issue 9, 2009, Pages 441-445

  Lee, Michael S ^a   Canan, Timothy ^a   Perlowski, Alice ^a   Bhatia, Ravi ^a   Jurewitz, Daniel ^a   Tobis, Jonathan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Death; Drug eluting stents; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN;

AGED; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG ELUTING STENT; FEMALE; GROUPS BY AGE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; INFECTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEOPLASM; ORTHOTOPIC TRANSPLANTATION; PERCUTANEOUS CORONARY INTERVENTION; RESPIRATORY FAILURE; SEX DIFFERENCE; STENT THROMBOSIS; SURVIVAL RATE; TERTIARY HEALTH CARE; UNITED STATES;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CAUSE OF DEATH; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; FEMALE; HEART FAILURE; HUMANS; KAPLAN-MEIERS ESTIMATE; KIDNEY FAILURE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RESPIRATORY INSUFFICIENCY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 71249120020     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
2. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
3. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
4. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: A meta-analysis. Eur Heart J 2006;27:2784-2814.
5. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents. J Am Coll Cardiol 2006;48:2584-2591.
6. Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006;113:1108-1113.
7. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-1019.
8. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of firstgeneration drug-eluting stents: A cause for concern. Circulation 2007;115:1440-1455.
9. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130.
10. Holmes DR Jr, Moses JW, Schofer J, et al. Causes of death with bare metal and sirolimus-eluting stents. Eur Heart J 2006;27:2815-2822.
11. Rathore S, Grayson AD, Sastry S, et al. Circumstances and mode of in-hospital death following 9,914 consecutive patients undergoing percutaneous coronary intervention in the Northwest of England. J Invasive Cardiol 2008;20:386-390.
12. Alpert JA, Thygesen K, Bassand JP, et al. Myocardial infarction redefined - A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-969. (Pubitemid 30681627)
13. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007;115:2344-2351.
14. Lash TL, Silliman RA. A comparison of the National Death Index and Social Security Administration database to ascertain vital status. Epidemiology 2001;12:259-261.
15. Malenka DJ, O'Rourke D, Miller MA, et al. Cause of in-hospital death in 12,232 consecutive patients undergoing percutaneous transluminal coronary angioplasty. The Northern New England Cardiovascular Disease Study Group. Am Heart J 1999;137:632-638.
16. Hannan EL, Wu C, Walford G, et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med 2008;358:331-341.
17. Fajadet J, Morice MC, Bode C, et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: Three-year results of the RAVEL trial. Circulation 2005;111:1040-1044.
18. Kelbaek H, Kløvgaard L, Helqvist S, et al. Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial. J Am Coll Cardiol 2008;51:2011-2016.
19. Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:989-997.
20. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel- eluting coronary stents. N Engl J Med 2007;356:998-1008.
21. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis. Lancet 2007;370:937-948.
22. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-1039.
23. James S, Carlsson J, Lindback J, et al. SCAAR - Long term mortality after drug eluting stents in Sweden, an additional year of follow-up. Presented at: European Society of Cardiology Annual Congress; September 1-5, 2007; Vienna, Austria (Clinical Trial Update I;1021).
24. Marzocchi A, Saia F, Piovaccari G, et al. Long-term safety and efficacy of drugeluting stents. Circulation 2007;115:3181-3188.
25. Marroquin OC, Selzer F, Mulukutla SR, et al. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med 2008;358:342-352.
26. Malenka DA, Kaplan AV, Lucas FL, et al. Outcomes following stenting in the era of bare-metal vs. the era of drug-eluting stents. JAMA 2008;299:2868-2876.
27. Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007;357:1393-1402.
28. Applegate RJ, Sacrinty MT, Kutcher MA, et al. Comparison of drug-eluting versus bare metal stents on later frequency of acute myocardial infarction and death. Am J Cardiol 2007;99:333-338.
29. Groeneveld PW, Matta MA, Greenhut AP, Yanf F. Drug-eluting compared with bare-metal coronary stents among elderly patients. J Am Coll Cardiol 2008;51:2017-2024.
30. Choi SH, Prasad A, Tsimikas S. The evolution of thienopyridine therapy. J Am Coll Cardiol 2008;51:2228-2229.
31. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;20:2001-2015. (Pubitemid 350106708)
32. Brar SS, Kim J, Brar SK, et al. Long-term outcomes by clopidogrel duration and stent type in a diabetic popoulation with de novo coronary artery lesions. J Am Coll Cardiol 2008;51:2220-2227.
33. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;296:159-168.